Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biological fit and clinical utility in upper tract urothelial carcinoma diagnostics: positioning Oncuria-Detect within an evidence-based, layered biomarker framework.

Translational andrology and urology·2026
Same author

[Perioperative and peri-interventional antibiotic prophylaxis: general and urology-specific recommendations from the German Interdisciplinary S3 guideline].

Urologie (Heidelberg, Germany)·2026
Same author

Surgical Reporting and Prognostic Stratification in Urachal Adenocarcinoma: Considerations Arising From a Recent Single-center Cohort Study.

Clinical genitourinary cancer·2026
Same author

Sweden's nationwide transition to transperineal prostate biopsy: implications for implementation across Europe.

Scandinavian journal of urology·2026
Same author

Digital PCR-Based Uromonitor for Molecular Detection of Bladder Cancer: A Multicenter Validation Study Comparing Quantitative PCR and Urine Cytology.

Clinical genitourinary cancer·2026
Same author

Robotic Partial Cystectomy and Extended Pelvic Lymph Node Dissection for Node-Positive Urachal Adenocarcinoma in a 34-Year-Old Woman: A Case Report.

Current oncology (Toronto, Ont.)·2026

Related Experiment Video

Updated: Jul 10, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

[From Opportunistic PSA Testing to Individualized, Risk-Adapted Early Detection of Prostate Cancer in Germany].

Matthias May1, Maximilian Burger2, Ingmar Wolff3

  • 1St. Elisabeth-Klinikum Straubing, Medizin-Campus Niederbayern (MCN), Klinik für Urologie, Deutschland, Straubing.

Aktuelle Urologie
|July 8, 2026
PubMed
Summary

Germany should adopt a structured, risk-adapted prostate cancer screening program starting at age 45. This approach emphasizes informed counseling and baseline prostate-specific antigen (PSA) testing for early detection, moving beyond opportunistic methods.

Area of Science:

  • Urology
  • Public Health
  • Oncology

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection
10:02

Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection

Published on: December 19, 2025

Related Experiment Videos

Last Updated: Jul 10, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection
10:02

Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection

Published on: December 19, 2025